Perspective Therapeutics, Inc. (CATX) has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. The radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 for imaging and alpha-particle targeted RPT using lead-212.
Thijs Spoor, CEO at Perspective Therapeutics, said: "This new license furthers our goal to bring new best-in-class products to the clinic that improve efficacy and minimize side effects."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.